Replies to post #453689 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

No PR before or coinciding with the event and no new material information will be presented.

I for one will not be paying for the privilege of hearing that non event.

[skitahoe]

Should the company be able to put the presentation on the website after the conference concludes?

What's really needed to make such presentations work as well as they could is the Journal being out, and the presenter being able to speak to, and enhance, what's in the Journal. That may not be the case for this presentation, but some day, hopefully soon, it will be.

I have no experience as to what the big conferences are for the diseases we're working on. In cancer I know people target on ASCO, AACR, etc. but I don't know about this. Can someone indicate when the really big conferences are held and whether they believe the company will be making presentations at one or more of these conferences.

As I gather it, the first real news we can anticipate is either filing an MAA, or issuance of a Journal. The company has more control of the filing of the MAA, but they may be reliant on contractors for certain aspects of the submission. As for a peer reviewed Journal, they have little or no control, if modifications are requested it's likely the lead clinician would coordinate making any changes. Like almost everything in biotech's things take longer than investors think, and often longer than management thinks as well.

Gary

[plexrec]

thanks William--" or E30 for every"--think I'll pass on this one--a bit pricey---unless of course an approval comes along with the talk--I'll reconsider